468 related articles for article (PubMed ID: 8758918)
1. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Geiger T; Müller M; Dean NM; Fabbro D
Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
[TBL] [Abstract][Full Text] [Related]
3. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
Yazaki T; Ahmad S; Chahlavi A; Zylber-Katz E; Dean NM; Rabkin SD; Martuza RL; Glazer RI
Mol Pharmacol; 1996 Aug; 50(2):236-42. PubMed ID: 8700129
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
5. Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA.
Song HF; Tang ZM; Yuan SJ; Zhu BZ; Liu XW
Acta Pharmacol Sin; 2003 Mar; 24(3):269-76. PubMed ID: 12617778
[TBL] [Abstract][Full Text] [Related]
6. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
Lee YS; Dlugosz AA; McKay R; Dean NM; Yuspa SH
Mol Carcinog; 1997 Jan; 18(1):44-53. PubMed ID: 9022812
[TBL] [Abstract][Full Text] [Related]
7. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
Wang XY; Repasky E; Liu HT
Exp Cell Res; 1999 Jul; 250(1):253-63. PubMed ID: 10388539
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism.
Chen CC; Wang JK; Lin SB
J Immunol; 1998 Dec; 161(11):6206-14. PubMed ID: 9834107
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.
Perlaky L; Saijo Y; Busch RK; Bennett CF; Mirabelli CK; Crooke ST; Busch H
Anticancer Drug Des; 1993 Feb; 8(1):3-14. PubMed ID: 8476501
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen AR; Halsey J; Fisher GA; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Sikic BI
Clin Cancer Res; 1999 Nov; 5(11):3357-63. PubMed ID: 10589745
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
Dean NM; McKay R
Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11762-6. PubMed ID: 7972137
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
McKay RA; Miraglia LJ; Cummins LL; Owens SR; Sasmor H; Dean NM
J Biol Chem; 1999 Jan; 274(3):1715-22. PubMed ID: 9880552
[TBL] [Abstract][Full Text] [Related]
16. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase1, a new target for antisense tumor therapy.
Elez R; Piiper A; Giannini CD; Brendel M; Zeuzem S
Biochem Biophys Res Commun; 2000 Mar; 269(2):352-6. PubMed ID: 10708555
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466.
Saijo Y; Perlaky L; Valdez BC; Wang H; Henning D; Busch H
Oncol Res; 1993; 5(8):283-91. PubMed ID: 8012060
[TBL] [Abstract][Full Text] [Related]
20. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
